

IDA Foundation

IDA Foundation is the world's leading not-for-profit supplier of essential, quality-assured medicines and medical supplies to low- and middle-income countries. Founded in 1972, our purpose is to make quality health-care accessible and affordable for those who are most in need of medicines and medical supplies.

We distribute over 3000 different medicines and medical supplies to over 100 countries. We serve governmental, non-governmental and private organisations, and our customers include Médecines Sans Frontières (MSF), the Clinton Health Access Initiative (CHAI), and the Global Drug Facility (GDF). Quality is central to everything we do, and we continually strive to improve our services, negotiate lower prices, and increase the availability of quality products worldwide.

People


Our people come from all over the world, from diverse educational and professional backgrounds. Our team is bound by passion for our mission: to improve access to and deliver high-quality essential medicines and medical supplies at the lowest possible price to low and middle-income countries. Representing 25 nationalities, our regional teams can often serve customers in their native language and are dedicated to finding procurement and supply chain solutions to ensure the road from supplier to patient is as efficient and reliable as possible.

Locations

Headquartered in Amsterdam, we are a global organisation. We have offices in India, China, Nigeria, D.R. Congo and the U.S., as well as representative agents in over 40 countries.

From the Netherlands, we supply essential medicines directly available from stock. We also facilitate direct, fast, and affordable shipments from other strategically located hubs to provide access to medicines and medical supplies around the world.

Our strong international presence gives us an excellent understanding of local markets to best match customers' needs with quality guaranteed products and services.



■ IDA offices
● IDA agents

GDP/GMP
certified



IDA

FOUNDATION



Photo: T. van der Leij



Making Quality Healthcare Affordable

Contact

IDA Foundation
Slochterweg 35
1027 AA Amsterdam
P.O. Box 37098
1030 AB Amsterdam
The Netherlands

order@idafoundation.org

Check our website for the latest news and product updates
www.idafoundation.org

Oncology

Prevention
Treatment
Palliative care

Copyright © 2015 IDA Foundation
1015-IDA-ONC-BR-1016

Cancer

Cancer has reached epidemic proportions worldwide. Today, it kills more people than HIV/AIDS, TB and Malaria combined. Despite the urgency of the cancer crisis, the international community has been slow to respond until recently. The newly established Sustainable Development Goals (SDGs) have set clear targets for fighting Non-Communicable Diseases (NCDs) and IDA is committed to playing a role.

While prevention and early detection are critical, we believe that affordable, quality assured treatment options can save many lives. And although cancer treatment is complex, as it may require surgery, radiation and chemo-hormonal therapy, medicines are already available for a number of priority cancers. Still, cancer treatment is often too expensive and not accessible for many.

IDA Foundation would like to make cancer medication more affordable and accessible in low- and middle-income countries as part of the other NCD medicines we supply.

In the past, HIV/AIDS and TB treatments were unavailable to many. By pooling procurement for HIV/AIDS and second-line TB treatment, customers needing small amounts of medicines were able to buy from us, thereby avoiding the high minimum order quantities that manufacturers required. We are applying the same approach for cancer medicines, keeping stock of high priority products for treatment of the most common forms of cancer. We believe this approach will bring treatment within reach for more patients in low- and middle income countries.

Photo: T. v.d. Leij

Facts

- *Cancers figure among the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012.*
- *Among men, the 5 most common sites of cancer diagnosed in 2012 were lung, prostate, colorectum, stomach, and liver cancer.*
- *Among women the 5 most common sites diagnosed were breast, colorectum, lung, cervix, and stomach cancer.*
- *Around one-third of cancer deaths are due to the 5 leading behavioural and dietary risks: high body mass index, low fruit and vegetable intake, lack of physical activity, tobacco use, alcohol use.*
- *Tobacco use is the most important risk factor for cancer causing around 20% of global cancer deaths and around 70% of global lung cancer deaths.*
- *Cancer-causing viral infections such as HBV/HCV and HPV are responsible for up to 20% of cancer deaths in low- and middle-income countries.*
- *More than 60% of the world's total new annual cases occur in Africa, Asia, and Central and South America. These regions account for 70% of the world's cancer deaths.*
- *It is expected that annual cancer cases will rise by 70%, from 14 million in 2012 to 22 million within the next 2 decades.*

Source: WHO Cancer factsheet 2015 / World Cancer Report 2014

Quality

Spanning the entire supply chain, our quality system for pharmaceutical products includes a comprehensive assessment based on manufacturing site approval, product approval, batch control and verification audits.

This strict Quality Assurance system is even more relevant as oncology medicines are currently not included in WHO's Pre-qualification Programme.

Why IDA

Customers choose IDA as their partner in supplying oncology medicines because we:

- supply high quality products, verified by IDA's Quality Affairs department
- set the quality standard, as WHO has no Non-Communicable Diseases (NCD) prequalification programme yet
- keep stock of most requested oncology medicines, allowing customers to procure smaller quantities
- offer a one-stop-shop for oncology and related NCD medicines
- give priority to identifying quality generics sources of oncology products
- have a strong network of global and local organisations, donors, as well as Ministries of Health and treatment centers

For more information, or an overview of all NCD medicines and supplies available, please contact the IDA Sales Department via order@idafoundation.org

Our Product Range

Prevention

More than 30%* of cancers are preventable through modification of behaviour and lifestyle. Prevention efforts often focus on risk factors including unhealthy diet, tobacco use, physical inactivity and use of alcohol. Addressing and limiting environmental and occupational exposure to carcinogens (cancer causing agents) can also have a significant impact on the incidence of cancer.

Some chronic infections are risk factors for cancer and have high prevalence in low- and middle-income countries. Hepatitis B virus (HBV) and hepatitis C virus (HCV) increase the risk of liver cancer. Some types of Human Papilloma Virus (HPV) and HIV infection both raise the risk of cervical cancer in women. Helicobacter pylori may increase the incidence of certain types of stomach cancer. Reducing exposure to these various infections – and treating them effectively when they do occur – is critical to cancer prevention efforts.

Treatment

Treatment involves a series of interventions, including surgery, radiotherapy, chemotherapy, and psychosocial support. This comprehensive approach is aimed at curing the disease or prolonging life considerably while improving patients' quality of life.

Palliative Care

Palliative care, including access to pain relief, is an urgent humanitarian need worldwide for children and adults with advanced cancers. Current estimates suggest that at least 2.9 million cancer and HIV/AIDS patients suffer the terminal phase of their disease with no pain relief. At the 67th World Health Assembly in May 2014, a ground-breaking resolution was adopted to drive national action to reduce barriers to the accessibility and availability of palliative care.

* NCD Alliance

Sources: uicc.org and cancer.org

IDA Product Range

Our oncology range is in line with the WHO Essential Medicines List (EML).

We have assessed and approved various generic oncology suppliers in order to have a comprehensive range of oncology products. Prices listed are in U.S. dollars and subject to change.

Antineoplastics & Immunosuppressives

	UOM	Price in \$
3038-002-16	asparaginase (L-asparaginase) 10,000 IU	800.00
3029-019-09	bleomycin 15 mg, 15,000 IU, powder for inj	10.30
3061-002-09	carboplatin 150 mg/15 ml, injection	17.25
3008-002-09	cisplatin injection 50 mg/50 ml	6.50
3026-002-F5	cyclophosphamide, powder for inj, 500 mg	1,002.46
3001-002-09	cytarabine 100 mg/5 ml, powder for inj	3.25
3055-019-16	dacarbazine 100 mg, powder for inj	33.60
3067-530-09	docetaxel 80 mg/2 ml, concentrate + solvent, 6 ml, injection	56.56
3032-019-09	doxorubicin HCl 10 mg, powder for inj	2.24
3027-019-09	doxorubicin HCl 50 mg, powder for inj	7.17
3050-002-09	etoposide 100 mg/5 ml, injection	1.79
3021-002-09	fluorouracil injection 250 mg/5 ml	1.23
3017-019-09	ifosfamide 1 g, powder for inj	6.10
3036-002-09	methotrexate 50 mg/2 ml, powder for inj	4.42
3030-002-32	methotrexate 2.5 mg, blister	5.77
3070-533-09	paclitaxel 6 mg/ml, 50 ml (300 mg), powder for inj	64.74
3039-002-R2	procarbazine 50 mg	69.33
3042-002-09	vincristine sulfate 1 mg/ml, injection	8.68

Medicines used in palliative care

2717-002-03	amitriptyline HCl 25 mg, coated	1000 tabs	7.11
4510-002-03	bisacodyl 5 mg, enteric coated tab	1000 tabs	6.50
2325-065-18	dexamethasone sodium phosphate 5 mg/ml, 1 ml, injection	100 amps	8.68
2732-002-03	diazepam 5 mg	1000 tabs	28.84
2742-002-18	diazepam 10 mg/2 ml, injection	100 amps	9.46
2710-002-63	fluoxetine 20 mg	30 caps	1.29
0252-002-03	ibuprofen 200 mg, film coated	1000 tabs	6.83
0253-002-15	ibuprofen 400 mg, film coated	500 tabs	6.72
4540-002-03	loperamide HCl 2 mg	1000 tabs	4.26
0905-002-03	metoclopramide HCl 10 mg	1000 tabs	9.30
0910-060-18	metoclopramide HCl 10 mg/2 ml, injection	100 amps	6.89
2749-002-20	midazolam 15 mg/3 ml, injection	10 amps	4.82
0289-083-32	morphine sulfate 30 mg controlled release	30 tabs	12.10
0286-060-20	morphine sulfate 10 mg/ml, 1 ml, injection	10 amps	5.10
0927-002-32	ondansetron 4 mg, blister	30 tabs	5.60
0925-002-49	ondansetron 4 mg/2 ml, injection	5 amps	1.46

